Price
Target price
€11.98
€11.98
-5.030%
-0.635
-5.030%
€27.97
17.07.26 / Frankfurt
WKN: A2AFXS / Symbol: CRVS / Name: Corvus / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Corvus Pharmaceuticals Inc Stock
Heavy losses for Corvus Pharmaceuticals Inc today as the stock fell by -€0.635 (-5.030%).
With 7 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
Based on the current price of 11.98 € the target price of 27 € shows a potential of 125.38% for Corvus Pharmaceuticals Inc which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Corvus Pharmaceuticals Inc stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Corvus Pharmaceuticals Inc in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corvus Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | -5.030% | -12.904% | 15.192% | 239.858% | 93.538% | 465.094% | 561.878% |
| Evolus Inc | -2.600% | -16.857% | -18.051% | -37.333% | -12.037% | -25.674% | -47.319% |
| Heron Therapeutics Inc. | 10.430% | 11.573% | 20.368% | -76.146% | -62.442% | -63.298% | -96.168% |
| Rhythm Pharmaceuticals | -1.620% | -4.211% | 9.639% | 18.182% | -2.674% | 519.048% | 475.949% |
Comments
Corvus Pharmaceuticals (CRVS) is now covered by The Goldman Sachs Group, Inc.. They set a "buy" rating on the stock.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals (CRVS) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $33.00 price target on the stock, up from $32.00.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Show more
Ratings data for CRVS provided by MarketBeat
News
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Immuno-oncology specialist Corvus Pharmaceuticals (NASDAQ:CRVS) reported a recent insider buy amid a year of sharp share price gains.
On June 11, 2026, David Scott Moore, acquired the direct
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
On May 15, 2026, Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals (NASDAQ:CRVS), acquiring 1,100,000 shares in the first quarter for an estimated $17.55 million based on
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall after multiple dips throughout January. However, that middling performance might
